Anaveon is a biopharmaceutical startup that focuses on the development of treatments for diseases related to immune system dysfunction. The company was established in 2017 by a group of immunologists and oncologists who are experts in the field of immunotherapy. They aim to utilize engineered cytokines, which are proteins that play a crucial role in cell signaling in the immune system, to create new treatments for diseases that currently have limited treatment options.

Anaveon operates in the healthcare market, specifically in the immuno-oncology sector. Its primary clients are patients suffering from diseases such as multiple myeloma and advanced melanoma, which are types of cancer that affect the immune system. The company's business model revolves around the research, development, and eventual commercialization of its treatments. It generates revenue through the funding it receives for its research and the potential sales of its treatments upon successful development and regulatory approval.

The company is currently in the clinical stage, meaning it is testing its treatments in clinical trials. It has presented its preclinical data and ongoing trials at various medical and oncology conferences, including the Society for Immunotherapy of Cancer (SITC) and the European Society for Medical Oncology (ESMO). These presentations are crucial for attracting further funding and partnerships.

Keywords: Biopharmaceutical, Immunotherapy, Cytokines, Immuno-Oncology, Clinical Trials, Multiple Myeloma, Advanced Melanoma, Immune System Dysfunction, Medical Conferences, Funding.